Standout Papers

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors ... 2018 2026 2020 2023 493
  1. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (2018)
    Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology

Immediate Impact

8 from Science/Nature 54 standout
Sub-graph 1 of 21

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
3 intermediate papers

Works of Sabine Bohnet being referenced

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
2018 Standout

Author Peers

Author Last Decade Papers Cites
Sabine Bohnet 681 600 108 185 50 1.1k
Wallace B. Morrison 680 158 103 143 40 1.1k
Robert E. Matus 883 203 214 168 34 1.3k
Pauline Rogers 308 330 82 188 57 1.4k
Kristine Burgess 713 164 166 173 40 1.1k
Cai Xu 375 350 124 186 70 1.2k
Paramjit Kaur 445 382 145 156 64 1.3k
Annette Smith 744 164 57 196 58 1.2k
K. Hahn 505 180 116 127 43 877
C. Kortsik 694 522 249 253 59 1.4k
Valérie J. Poirier 452 145 85 258 48 958

All Works

Loading papers...

Rankless by CCL
2026